Trial reportLasers in medical science2026
Subthreshold micropulse laser for subretinal fluid after vitrectomy in myopic traction maculopathy: a pilot randomized controlled trial.
Trial report in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the effectiveness and safety of subthreshold micropulse laser (MPL) in patients with residual subretinal fluid (SRF) after vitrectomy for myopic traction maculopathy (MTM). This was a prospective, pilot randomized controlled trial. We recruited eyes with residual SRF≥200 μm on OCT at 1-month follow-up after vitrectomy for macular hole retinal detachment (MHRD) and macular schisis with foveal detachment (MSRD). Forty eligible patients were randomized to control and MPL group in a 1:1 allocation ratio. Patients in the MPL group received MPL treatment 1-month after surgery by a same doctor and the procedure was repeated at 1-month intervals when necessary. Follow-up endpoint was defined as either complete absorption of subretinal fluid (SRF) or a minimum postoperative observation period of 6 months. The median follow-up time was 6 months (range: 3-28 months). Postoperatively, BCVA was significantly improved, and macular thickness was significantly reduced (P < 0.001) compared with preoperative baseline. The patients in the MPL group received 2.05 ± 0.89 (range 1-3) times of MPL. The Kaplan Meier curve showed a trend that the MPL group had better SRF absorption, but the difference is not significant between the two groups (P = 0.33). No severe complications in both groups during the follow-up. MPL is a safe non-invasive procedure in pathologic myopia patients. The limited therapeutic effect of MPL on SRF absorption may reflect the compromised RPE function resulting from progressive thinning and atrophy in highly myopic eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.